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Ingesting a Bitter Solution: The Sweet Touch to Increasing
Short-Term Cycling Performance
Naroa Etxebarria, Megan L. Ross, Brad Clark, and Louise M. Burke
Purpose: The authors investigated the potential benefit of ingesting 2 mM of quinine (bitter tastant) on a 3000-m cycling time-
trial (TT) performance. Methods: Nine well-trained male cyclists (maximal aerobic power: 386 [38] W) performed a maximal
incremental cycling ergometer test, three 3000-m familiarization TTs, and four 3000-m intervention TTs (∼4 min) on consecutive
days. The 4 interventions were (1) 25 mL of placebo, (2) a 25-mL sweet solution, and (3) and (4) repeat 25 mL of 2-mM quinine
solutions (Bitter1 and Bitter2), 30 s before each trial. Participants self-selected their gears and were only aware of distance
covered.Results:Overall mean power output for the full 3000mwas similar for all 4 conditions: placebo, 348 (45)W; sweet, 355
(47) W; Bitter1, 354 (47) W; and Bitter2, 355 (48) W. However, quinine administration in Bitter1 and Bitter2 increased power
output during the first kilometer by 15 ± 11 W and 21 ± 10 W (mean ± 90% confidence limits), respectively, over placebo,
followed by a decay of 34 ± 32 W during Bitter1 and Bitter2 during the second kilometer. Bitter2 also induced a 11 ± 13-W
increase during the first kilometer compared with the sweet condition. Conclusions: Ingesting 2 mM of quinine can improve
cycling performance during the first one-third of a 3000-m TT and could be used for sporting events lasting ∼80 s to potentially
improve overall performance.
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A recent addition to the range of acute nutrition strategies that
can be undertaken on competition day to enhance sport per-
formance is the intake of certain dietary components and tastants
to exploit the sensory outcomes that are achieved by exposing
receptors in the mouth and gastrointestinal tract to these ingredi-
ents.1 This new area of sport nutrition, typically known as “mouth
rinsing,” emerged from observations of the performance benefits
of carbohydrate (CHO) intake during shorter (∼1 h) protocols of
sustained higher-intensity exercise. During these shorter protocols,
CHO was unlikely to play its typical metabolic role of addressing
fuel limitations in the muscle.2 Once it was established that these
benefits only occurred when CHO was placed in the oral space,2
rather than being infused directly into the bloodstream,3 a new
branch of research on interactions between oral receptors to CHO
and the central nervous system was springboarded. There is now
robust evidence that the exposure (5–10 s) of these receptors to
CHO activates areas in the brain that control perceptions of effort
and pacing decisions. This activation creates a cascade of events
that signal energy provision and enhance exercise capacity and
performance.1 These benefits are specific to CHO rather than
sweetness and can be repeatedly exploited during sporting proto-
cols involving ∼1 hour maximal sustained or intermittent exercise.1
This has led to the further investigation of other nutrients, food
chemicals, and tastants that might have sensory-driven effects of
value to sports performance. Positive outcomes have already been
identified for the gut sensing of caffeine, fluid, acetic acid, menthol,
and quinine.1
Quinine, a bitter tasting solution originating from the bark
of the cinchona tree, has been shown to enhance capacity for
short-term maximal cycling performance by 2.5% to 4%.4 The
activation of bitter taste receptors in the oral cavity and upper
gastrointestinal tract appears to increase corticomotor excitability5
and, in turn, improve cycling efforts requiring maximal effort.
However, unlike the case for CHO mouth rinsing, the quinine
solution needs to be ingested for it to prove effective,6 as the
specific receptors are concentrated in the back of the mouth and
throat. Furthermore, current evidence of efficacy is limited to a
30-second maximal cycling effort. Although these data are of
interest to track cyclists, it is unknown if the findings are transfer-
rable to events of longer duration. Therefore, the aim of this study
was to quantify the effects of 2-mM quinine ingestion prior to a
3000-m maximal cycling TT. This protocol was chosen, as we
anticipated a duration of approximately 4 minutes in highly trained
cyclists to mirror the competition times of elite track endurance




Nine well-trained male participants were recruited for the study
(body mass: 78 [11] kg; height: 181 [7] cm; age: 36 [8] y; and
maximal aerobic power, MAP: 386 [38] W). Participants had a
cycling training history of at least 3 years and completed a pre-
participation screening questionnaire to ensure they were injury-free
and healthy before participating in the study.
Study Design
We implemented a randomized counterbalanced single-group
design to evaluate the effects of quinine (Bitter1 and Bitter2),
water (Placebo), and a sweet drink (Sweet). We duplicated the
quinine intervention to test the reliability of its effects. The study
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was approved by the Committee for Ethics in Human Research at
the University of Canberra and according to the Helsinki Declara-
tion. All participants provided their written informed consent
before participating.
Methodology
Pretrial Standardization. A standardized pretrial meal was pro-
vided to participants before all trials (familiarization and inter-
vention) to minimize variation in macronutrient availability prior
to exercise. The meal was consumed 2 hours prior to the trial,
provided 2 g·CHO·kg·BM−1 and consisted of raisin toast, marga-
rine, honey, jam, banana, a 250-mL liquid breakfast, and confec-
tionary, with the combination and amount of the foods being
individually adjusted to the body mass of the participants.
ExerciseProtocol. Participants performed amaximal incremental
test, three 3000-m familiarization time trials (TT), and four 3000-m
experimental TT involving 4 different interventions over the course
of 7 separate visits to the laboratory. During the first visit, parti-
cipants completed a 10-minute warm-up at 100 W followed by a
3-minute break prior to the start of a maximal, progressive incre-
mental test on a cycle ergometer (starting at 100 W with 5 W
increments every 15 s until volitional fatigue). The power output
of the last minute of the test was then averaged to estimate the
participants’maximal aerobic power (MAP). After a brief 5-minute
cool down and 30-minute rest, the cyclists remounted the cycle
ergometer and commenced their first familiarization 3000-m TT.
The 3 familiarization trials mimicked exactly the subsequent
4 intervention trials and they were undertaken to help the cyclists
understand the protocol the cycle ergometer and the instructions
provided before each TT. These familiarization trials also enabled
us to reduce the effect of any potential learning effect on subsequent
experimental trials. Similar trials have been shown to reduce the
coefficient of variation from 1.2% between the first 2 familiarization
trials to 0.2% with subsequent familiarization trials.7 The exercise
protocol for all seven 3000-m TT completed during the study
commenced with a 10-minute incremental (submaximal) warm-
up consisting of the following: 4 minutes at 50% of their MAP,
3 minutes at 60% MAP, 2 minutes at 70% MAP, and 1 minute at
80%MAP.8 At the end of the warm-up, participants were instructed
to stop pedaling but remain seated on the cycle ergometer for
2.5 minutes, after which they were given a solution (Placebo for
all familiarization trials and the randomized treatment during the
intervention trials) to swirl in their oral cavity for 10 seconds before
ingesting it. During the 20 seconds after ingesting the solution and
prior to the commencement of the 3000-m TT, the principal
researcher read out TT instructions followed by the final countdown
for the start of the TT. The instruction was “This is a maximal
performance trial, you should give your best effort you have on the
day, each and every day. You are free to change gears during the
TT as you see fit and can adopt your own pacing strategy.”
All TTs were performed on a Velotron Dynafit Pro (RacerMate
Inc, Seattle, WA) cycle ergometer (validity ± 1.5%; reliability
<0.2%), which was paired with the associated Velotron 3D soft-
ware. Participants were able to view their progress along the course
on a large television screen that also showed distance covered;
however, they were blinded to power output, cadence, and any
other feedback. The cycle ergometer was checked against the
Australian Institute of Sport’s dynamic calibration rig9 before
testing, and the Velotron CS AccuWatt verification function
(RacerMate Inc) was used between tests to ensure power output
measurement was within factory calibration. Participants could
self-select their gear at the start of each trial and were free to change
them during the TT as they saw fit. Power output (W), cadence
in revolutions per minute (rpm), and heart rate (HR) in beats per
minute (bpm) were monitored continuously during all trials. The
position on the cycle ergometer for all cyclists was standardized
between tests. Rating of perceived exertion (RPE) was recorded at
the end of each trial scale (6–20 units).
Pacing Index was calculated to represent the percentage of
power output sustained for each 150-m split in relation to the entire
3000-m TT. This index, or similar ones related to cycling velocity,
have been previously used to reflect the relative effort for each split
in relation to the entire effort in various studies.10,11
Pacing Index = ðpower output for each 150-m split × 100=
overall power output for 3000-m TTÞ − 100
Intervention Solutions. The 4 treatments, administered in a
randomized and counterbalanced manner 30 seconds prior to the
TT commencement, were (1) 25mL of Placebo (water), (2) a 25-mL
diet cordial (Cottee’s; Schweppes, Melbourne, Australia) solu-
tion (Sweet), and (3) and (4) repeat administration of 25 mL of
2-mM quinine solution (Quinine Hydrochloride Dehydrate, S1125;
Sigma-Aldrich Pty Ltd, Castle Hills, Australia), named Bitter1 and
Bitter2. As it was impossible to disguise the taste of the quinine to
provide a true blinded Placebo, we used the sweet solution as a
distraction to the real purpose of the investigation. At the time of
conducting the study, the subjects were unaware of the hypotheses
regarding mouth rinsing with bitter tastants but were knowledge-
able about the benefits of CHO rinsing. We used a concentrated
sweetened diet cordial with the same color as the 2 bitter solutions
and free of CHO in view that the mouth-rinsing benefit is achieved
by CHO rather than sweetness per se.1
Statistical Analysis
Descriptive data are presented as mean (SD). All raw and derived
data were collated, checked for outliers, and corrected for any
errors. All data was log-transformed, then back-transformed to
obtain changes in means and variation as a percent.12 A crossover
group analysis was employed to estimate the mean difference
between interventions. Data modeling involved estimation of the
true unknown difference between the 4 interventions and interval
estimates of the uncertainty about the value of these parameters.
Within- and between-participant variability in power output for
each intervention are reported as the percent coefficient of varia-
tion. The magnitude of change between the standardized means
(effect size) was interpreted against the following criteria: <0.2,
trivial; 0.2 to 0.6, small; 0.6 to 1.2, moderate; 1.2 to 2.0, large;
and >2.0, very large. Precision of estimation was determined using
90% confidence limits (CL). When the magnitude of the standard-
ized effect crossed the threshold of a small positive and small
negative (±0.2), the change or difference was deemed unclear.
Results
Power Output
There was no substantial ergogenic effect of quinine on overall
3000-m TT cycling performance as the mean power output for all 4
conditions was similar: Placebo, 348 (45) W; Sweet, 355 (47) W;
Bitter1, 354 (47) W; and Bitter2, 355 (48) W. However, quinine
administration increased power output during the first kilometer by
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∼18 ± 4 W (mean difference ± 90% CL) over the Placebo interven-
tion, and by ∼8 ± 4 W compared with the Sweet intervention,
followed by a steep decay in power output of 25 to 43W during the
second kilometer (Table 1). The Sweet and Placebo conditions had
a smaller decay in power output in the second kilometer (20 and
17 W, respectively). The power output during the third kilometer
was similar between conditions: Placebo, 358 (61) W; Sweet, 361
(64) W; Bitter1, 358 (69) W; and Bitter2, 355 (63) W.
The familiarization trials served their purpose to decrease
performance variability and remove any learning effect on 3000-m
TT performance, with a 4.5% increase in power output from
familiarization trial 1 to 2 and only a 1% increase in power output
from familiarization trial 2 to 3 (334–349 W and 349–353 W,
respectively).
Pacing
Power output for every 150-m split of the TT shows that the effects
of quinine were most noticeable between 450 and 900 m, with both
Bitter conditions showing an increase of 18 to 30 W ± 10 to 19 W
(mean difference ± 90%CL) compared with Placebo (Figure 1) and
an increase of 12 to 20 W ± 12 to 17 W during Bitter2 compared
with Sweet (Figure 2). The Bitter1 condition also induced a 12 ±
10W increase in power output compared with the Sweet condition.
There were no significant differences between any of the conditions
during the last 1000 m. The Pacing Index calculated for each of the
150-m splits for all interventions shows a similar trend to the pacing
described as power output (Figure 3).
Cadence, Heart Rate, and Perceived Exertion
The mean cadence sustained for the entirety of the 3000 m during
all 4 interventions was similar: Placebo, 107 (6) rpm; Sweet,
108 (6) rpm; Bitter1, 108 (6) rpm; and Bitter2, 108 (8) rpm. The
cadence was also comparable during the first, second, and third
kilometer of the TT.
The mean heart rate for all 4 interventions was similar:
Placebo, 164 (9) bpm; Sweet, 168 (11) bpm; Bitter1, 166 (12)
bpm; and Bitter2, 168 (9) bpm. The answer to the question “how
much of yourself did you give?” for each one of the conditions were
also similar: Placebo, 95%; Sweet, 94%; Bitter1, 96%; and Bitter2,
95%. There were mainly unclear differences between the inter-
ventions in regard to the RPE given large uncertainty, with a small
difference in RPE after Bitter2 (19 ± 1) condition compared with
Placebo (18 ± 2; mean difference ±90% CL). The RPE of Bitter1
intervention was rated 19 (2) and the Sweet intervention was
rated 17 (4).
Discussion
The primary aim of this investigation was to examine the effect
of ingesting a bitter solution on 3000-m cycling performance.
Although the bitter solution (quinine) did not improve overall
3000-m TT performance, power output was higher in the initial
third of the TT and particularly during the 40 to 80 seconds after
quinine ingestion. However, the increased physiological cost of
higher power output during the initial third may have led to an
observed reduction in power output through the middle section
(second kilometer) of the TT compared with Sweet and Placebo
trials such that any potential performance benefits conferred by the
initial increase in power output were diminished.
This study supports the concept that quinine ingestion in-
creases short-term (30 s) power output, although the ergogenic
benefits from it lasted even longer for up to 80 seconds. However,
it is also plausible that while the body generates superior power
output as a consequence of quinine ingestion, it consequently
struggles with the physiological consequences of this higher in-
tensity causing downregulation of the pacing strategy straight after.
As the last third of all TT are similar, the steeper decline in power
output during the second kilometer after quinine ingestion subsided
by the third kilometer. Therefore, it is possible that athletes can use
Table 1 Standardized Differences ± 90% CL for Power Output (W) Between Interventions for the 3000-m Time Trial
and the First, Second, and Third Kilometers of the 3000-m Time Trial
3000-m time trial First kilometer Second kilometer Third kilometer








































































Abbreviations: CL, confidence limits; ES, effect size. Note: Standardized differences ± 90% CL, mean power output ± 90% CL, and ES as specified. The values in bold
show a substantial or meaningful difference.
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quinine ingestion as a training strategy to produce higher power
output or speeds and subsequent greater metabolic adaptations
that evoke enhanced overall performances.
In our study, we saw the greatest effect of quinine during the
450 to 900 m section (∼40 to 80 s), which is approximately
1 minute after ingesting the solution. This observation might be
related to the timing of the ingestion of the bitter solution, and
future work might look into this. Regardless, the first kilometer
(∼80 s) of the TT generated substantially higher power output in
both quinine interventions compared with the Placebo intervention.
Nevertheless, the differences between the quinine interventions
and the Sweet condition with 0% CHO were not as robust. There is
evidence that exercise performance is improved after ingesting
nonsweet CHO such as maltodextrin, suggesting that it is not the
sweetness of the solution that triggers a response, but it is CHO
specific. It is known that CHO induces a taste transduction pathway
that responds to CHO independently of those for sweetness.13–17
Perhaps the Sweet condition managed to have a Placebo effect to a
certain extent; however, the quinine conditions proved to have a
higher positive impact during the early stages of the TT.
The consistency in cadence during the 4 interventions suggests
that the cyclists were highly skilled at finding the cadence at which
they are most comfortable. Despite the 150- to 200-W difference in
power output during the lead position (550–600 W), and following
the lead in second, third, or fourth positions (350–400 W), riders
kept a narrow range in cadence.18 In this study, participants were
Figure 1 — Individual responses to the different treatments during the first 1200 m for each 300-m split during the 3000-m time trial.
Figure 2 — Power output for all 4 experimental conditions for the 150-m splits, standardized differences ± 90% confidence limits. Cohen small effect-
size differences (0.2–0.6) are identified as follows: #, Bitter1 −Sweet; *, Bitter2 − Sweet; ◊, Bitter1 − Placebo; ‡, Bitter2 − Placebo; and Δ,
Bitter1 −Bitter2. TT indicates time trial.
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free to change gears to accommodate a higher or lower capacity to
produce power output throughout the TT during any given inter-
vention, which is not the case in track cycling where they perform
at a fixed gear.
Practical Applications
The ability to sustain high power outputs for relatively short periods
of time is a crucial asset in many sports, including a 4-km TT. Using
the example of the pursuit TT in track cycling, the pacing strategy
of a rider who is completing the effort solo (less variability in power
output throughout the event) is quite different to that performed as
part of a team. In this study, it is apparent that quinine administration
would potentially benefit the lead-off rider of a team pursuit at the
start of the event rather than the riders competing in the individual
pursuit. The lead-off rider in the team pursuit is required to lead the
team from a static start to high speeds and produce a power output
that is 30% to 35% higher than the teammates following.19 This
extra effort required is as a consequence of the given drag he/she
faces being positioned at the front and the benefit of a drafting effect
obtained by the other 3 cyclists.13,14 It is important to remember that
this study focuses on individual performance for the entire TT;
however, the team pursuit has other characteristics that were not
necessarily reproduced in this study. For example, once the lead
rider has set up the pace and moves toward the back of the group,
power output demands decrease.15 The rider in first position could
ingest the bitter solution for the first kilometer, without being
affected by the consequent decrease in power output as the demands
also decrease in that situation.
It is worth considering the possible applications of quinine
ingestion in the different sporting events and contexts. For exam-
ple, given the greater decay in power output observed during the
second kilometer after quinine ingestion, it might be more appro-
priate to ingest quinine toward the end of an event rather than at the
beginning (ie, 800-m track and field, 2000-m rowing, track cycling
team pursuit, etc). It is also worth considering the potential for
sporting events lasting ∼80 seconds in order to improve overall
performance, which is the time frame that we showed quinine
having an effect in this study. There is an opportunity, practicality
of quinine delivery permitting, to benefit from quinine during the
middle stages of an effort lasting 3 to 4 minutes (ie, 1500 m in track
and field or a 2000-m rowing race). The use of any ergogenic aid is
always context specific, and different individuals may not respond
the same way either. Thus, it is always important to keep in mind
that quinine ingestion should be trialed with the individual athlete
in training first before testing it in competition. Furthermore, the
mode of ingestion of quinine in its fluid form used in this study
might not suit many sporting environments, and other routes of
ingestion (ie, lozenge or gum) may need further consideration.
Conclusions
Despite a similar overall performance for the 3000-m TT for all 4
interventions, the difference in the pacing strategy freely imple-
mented by the participants indicates that quinine ingestion has the
potential to improve team pursuit in track cycling, especially during
the early stages of the lead-off rider.
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